Disease · MONDO_0005059
leukemia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. leukemia. Diseases, record MONDO_0005059. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005059
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- blood (leukemia), leukaemia (disease), leukemia (disease), leukemia, malignant, leukemias, leukemias, general
- Open Targets
Drugs182
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BUSULFAN | CHEMBL820 | Small molecule | Approval | DailyMed | 21 | 20 | 20 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Approval | DailyMed | 16 | 9 | 9 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Approval | DailyMed | 6 | 5 | 5 | Drugs and targets |
| RASBURICASE | CHEMBL1201594 | Enzyme | Approval | DailyMed | 4 | 3 | 3 | Drugs and targets |
| ALLOPURINOL | CHEMBL1467 | Small molecule | Approval | DailyMed | 52 | 1 | 1 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| CORTISONE ACETATE | CHEMBL1650 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| DEXAMETHASONE SODIUM PHOSPHATE | CHEMBL2021430 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| HYDROCORTISONE | CHEMBL389621 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| METHYLPREDNISOLONE ACETATE | CHEMBL1364144 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 182
See all 182 drugsTargets220
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 10 | Glucocorticoid receptor agonist | Approval | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 8 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 8 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 3 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 6 | Bcr/Abl fusion protein inhibitor | Phase 2 | https://conductscience.org/library/genes/613 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 5 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 5 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 5 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 5 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 5 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5424 | Drugs and targets |
| POLD2 | DNA polymerase (alpha/delta/epsilon) | 5 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5425 | Drugs and targets |
1 to 10 of 220
See all 220 targetsTrials215
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01190930 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | Phase 3 | 9,350 | 2020-06-23 | Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive | CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE SULFATE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01522976 | Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | Phase 2 | 282 | 2016-03-22 | Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia | AZACITIDINE, LENALIDOMIDE, VORINOSTAT | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00230178 | Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome | Phase 3 | 280 | 2009-12-31 | Tumor Lysis Syndrome, Cancer, Hyperuricemia | ALLOPURINOL, RASBURICASE | Its record names the disease | ClinicalTrials.gov |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | Phase 2 | 201 | 2023-06-29 | Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Diseases, Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome | BUSULFAN, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT01376310 | GSK1120212 Rollover Study | Phase 2 | 159 | 2019-02-19 | Cancer | CARBOPLATIN, DOCETAXEL, ERLOTINIB, EVEROLIMUS, GEMCITABINE, PEMETREXED, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00658814 | Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | Phase 2 | 133 | 2014-01-06 | Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Secondary Acute Myeloid Leukemia | AZACITIDINE, GEMTUZUMAB OZOGAMICIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00390793 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | Phase 2 | 107 | 2025-02-17 | Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, t(9;22) | CYCLOPHOSPHAMIDE, CYTARABINE, DASATINIB ANHYDROUS, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PREDNISONE, VINCRISTINE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00357500 | Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | Phase 2 | 101 | 2014-09-09 | Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific | CELECOXIB, CYCLOPHOSPHAMIDE, ETOPOSIDE, FENOFIBRATE, THALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | Phase 2 | 97 | 2017-04-26 | Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia | CYCLOPHOSPHAMIDE, CYTARABINE, DASATINIB ANHYDROUS, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, LEUCOVORIN CALCIUM, METHOTREXATE, METHYLPREDNISOLONE, PREDNISONE, SIROLIMUS, TACROLIMUS ANHYDROUS, VINCRISTINE SULFATE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00943592 | Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | Phase 1/2 | 82 | 2014-02-27 | Advanced Hematologic Malignancies, Leukemia, Preleukemia | ALEMTUZUMAB, CLOFARABINE, MELPHALAN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 215
See all 215 trialsComparisons in its trials37
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Overall Survival | 16 of 49 | 47 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Non-Relapse Mortality Rate (NRM) | 2 of 49 | 8 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Overall Survival | 29 of 49 | 93 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: deaths from any cause | 31 of 49 | 93 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: serious adverse events | 6 of 49 | 8 of 150 | 199 | NCT01572662 | Trial comparisons |
| Cohort A (GSK1120212 < 24 Weeks) vs Cohort B (GSK1120212 >= 24 Weeks): deaths from any cause | 13 of 126 | 3 of 33 | 159 | NCT01376310 | Trial comparisons |
| Cohort A (GSK1120212 < 24 Weeks) vs Cohort B (GSK1120212 >= 24 Weeks): serious adverse events | 26 of 126 | 13 of 33 | 159 | NCT01376310 | Trial comparisons |
| G-CSF (Granulocyte Colony- Stimulating Factor) vs G-CSF and GM-CSF (Granulocyte Macrophage): serious adverse events | 7 of 25 | 7 of 25 | 50 | NCT00208949 | Trial comparisons |
| Arm I: Glutamine vs Arm II: Placebo: Incidence of Vincristine-induced Peripheral Neuropathy | 24 of 24 | 25 of 25 | 49 | NCT00365768 | Trial comparisons |
| Arm I: Glutamine vs Arm II: Placebo: Number of Participants With Progression of Neuropathy | 11 of 24 | 19 of 25 | 49 | NCT00365768 | Trial comparisons |
1 to 10 of 37
See all 37 comparisons in its trialsPapers from its trials101
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005059
GET https://conductscience.org/api/diseases/v1/MONDO_0005059/drugs?page=2